The earnings call was largely positive, highlighting successful trial results, a strong financial position, and clear plans for future clinical development. While there were increased expenses and a reported net loss, these were balanced by significant achievements and forward-looking strategies.

Company Guidance

During the Trevi Therapeutics Second Quarter 2025 Earnings Conference Call, significant guidance was provided concerning the company's clinical and financial outlook. Trevi raised approximately $115 million in capital, resulting in a total cash and investment balance of around $204 million as of June 30, 2025, providing a financial runway into 2029. The company plans to initiate several clinical trials, including two Phase III trials for Haduvio in chronic cough associated with idiopathic pulmonary fibrosis (IPF) and a separate trial for non-IPF interstitial lung disease cough, projected to launch in the first half of 2026. The CORAL trial produced positive results, showing significant reductions in 24-hour cough frequency and improvements in quality of life as measured by the Leicester Cough Questionnaire. Additionally, discussions with the FDA for an end-of-Phase II meeting are expected in the fourth quarter of 2025 to finalize the Phase III program plans. Financially, Trevi reported a net loss of $12.3 million for Q2 2025, with R&D expenses slightly decreasing to $9.4 million and G&A expenses increasing to $4.3 million, mainly due to rising professional fees and headcount.

Successful Data Readouts

Positive data readouts from both the CORAL trial for chronic cough in IPF patients and the RIVER trial for RCC patients, leading to significant progress in clinical development.

Strong Financial Position

Raised approximately $115 million, resulting in total cash and investments of approximately $204 million as of June 30, 2025, providing a solid financial runway into 2029.

CORAL Trial Success

The CORAL trial met the primary endpoint with statistically significant reduction in 24-hour cough frequency and significant improvements in quality of life assessments using the Leicester Cough Questionnaire.

Planned Phase III Trials

Plans to initiate Phase III trials for chronic cough in IPF patients and a study for non-IPF interstitial lung diseases, expanding the potential market.

Advancement in Drug-Drug Interaction Studies

Ongoing Phase I studies, including a drug-drug interaction study, are expected to provide crucial data for the end of Phase II meeting with the FDA.

Trevi Therapeutics (TRVI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TRVI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.10 / -	-0.13	―	―	―
Aug 07, 2025	2025 (Q2)	-0.10 / -0.09	-0.12	25.00% (+0.03)	―
May 08, 2025	2025 (Q1)	-0.12 / -0.09	-0.11	18.18% (+0.02)	―
Mar 18, 2025	2024 (Q4)	-0.13 / -0.11	-0.08	-37.50% (-0.03)	―
Nov 06, 2024	2024 (Q3)	-0.12 / -0.13	-0.08	-62.50% (-0.05)	―
Aug 08, 2024	2024 (Q2)	-0.11 / -0.12	-0.07	-71.43% (-0.05)	―
May 07, 2024	2024 (Q1)	-0.09 / -0.11	-0.06	-83.33% (-0.05)	―
Mar 20, 2024	2023 (Q4)	-0.09 / -0.08	-0.06	-33.33% (-0.02)	―
Nov 09, 2023	2023 (Q3)	-0.09 / -0.08	-0.12	33.33% (+0.04)	―
Aug 10, 2023	2023 (Q2)	-0.09 / -0.07	-0.14	50.00% (+0.07)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TRVI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$7.30	$7.42	+1.64%
May 08, 2025	$6.60	$6.60	0.00%
Mar 18, 2025	$6.56	$6.81	+3.81%
Nov 06, 2024	$3.10	$2.90	-6.45%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Trevi Therapeutics Inc (TRVI) report earnings?

Trevi Therapeutics Inc (TRVI) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Trevi Therapeutics Inc (TRVI) earnings time?

Trevi Therapeutics Inc (TRVI) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TRVI EPS forecast?

TRVI EPS forecast for the fiscal quarter 2025 (Q3) is -0.1.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing